Vera Therapeutics to Present at Upcoming Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 /CourierPR/ -- Vera Therapeutics, a biotechnology company focused on autoimmune diseases, will participate in upcoming investor conferences to discuss its flagship product and future plans.

The company’s management team will present at two major investor events in New York City in September 2026. The first event, the Cantor Global Healthcare Conference, will take place on September 10. At this conference, Vera Therapeutics will host a fireside chat and one-on-one investor meetings. The webcast of the conference will be available for 90 days following the event. The second event, the Morgan Stanley 24th Annual Global Healthcare Conference, will be held on September 15. At this conference, Vera Therapeutics will also offer a fireside chat and one-on-one investor meetings. A replay of the webcast will be accessible through the company’s website.

TRUTAKNA™ (atacicept-vymj), Vera Therapeutics' commercial product, is a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor aimed at transforming medicine in autoimmune diseases, particularly focusing on kidney conditions. The company is exploring the potential of this product in multiple autoimmune diseases where reducing autoantibodies through BAFF and APRIL inhibition could be beneficial.

Founded in 2016 and headquartered in Brisbane, California, Vera Therapeutics has been actively advancing its product pipeline. The company’s forward-looking statements highlight its commitment to research and development in the field of autoimmune diseases. However, the company cautions that these statements are subject to various risks and uncertainties, including the potential for different outcomes in clinical trials and the regulatory approval process.

For further details, interested parties can visit the News & Events section of Vera Therapeutics' website, which will provide access to the webcasts of the upcoming conferences.